AU2017241837B2 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith - Google Patents

Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith Download PDF

Info

Publication number
AU2017241837B2
AU2017241837B2 AU2017241837A AU2017241837A AU2017241837B2 AU 2017241837 B2 AU2017241837 B2 AU 2017241837B2 AU 2017241837 A AU2017241837 A AU 2017241837A AU 2017241837 A AU2017241837 A AU 2017241837A AU 2017241837 B2 AU2017241837 B2 AU 2017241837B2
Authority
AU
Australia
Prior art keywords
purin
cyclohexanecarboxamide
ylamino
chloro
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017241837A
Other languages
English (en)
Other versions
AU2017241837A1 (en
Inventor
John F. Boylan
Gordon L. BRAY
Ellen Filvaroff
Robert Hubbard
David Mikolon
Heather Raymon
Tao Shi
Tam M. Tran
Toshiya Tsuji
Lilly L. Wong
Suichan Xu
Dan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of AU2017241837A1 publication Critical patent/AU2017241837A1/en
Application granted granted Critical
Publication of AU2017241837B2 publication Critical patent/AU2017241837B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017241837A 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith Active AU2017241837B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317412P 2016-04-01 2016-04-01
US62/317,412 2016-04-01
PCT/US2017/025252 WO2017173206A1 (en) 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
AU2017241837A1 AU2017241837A1 (en) 2018-10-25
AU2017241837B2 true AU2017241837B2 (en) 2021-07-22

Family

ID=59959573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017241837A Active AU2017241837B2 (en) 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Country Status (15)

Country Link
US (1) US10576085B2 (cg-RX-API-DMAC7.html)
EP (1) EP3436018A4 (cg-RX-API-DMAC7.html)
JP (1) JP7014731B2 (cg-RX-API-DMAC7.html)
KR (1) KR102356433B1 (cg-RX-API-DMAC7.html)
CN (1) CN109069512B (cg-RX-API-DMAC7.html)
AU (1) AU2017241837B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070163A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018986A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018002787A1 (cg-RX-API-DMAC7.html)
EA (1) EA039392B1 (cg-RX-API-DMAC7.html)
IL (1) IL262007B2 (cg-RX-API-DMAC7.html)
MX (1) MX379513B (cg-RX-API-DMAC7.html)
NZ (1) NZ746554A (cg-RX-API-DMAC7.html)
SG (2) SG10202009589UA (cg-RX-API-DMAC7.html)
WO (1) WO2017173206A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
IL288519B2 (en) 2015-11-02 2023-09-01 Blueprint Medicines Corp inhibitors of ret
US10913716B2 (en) 2016-03-31 2021-02-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6995058B2 (ja) 2016-04-01 2022-02-21 シグナル ファーマシューティカルズ，エルエルシー （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
CA3013408A1 (en) 2016-04-01 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
US10543214B2 (en) 2017-10-04 2020-01-28 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
HRP20240124T1 (hr) 2018-04-03 2024-04-12 Blueprint Medicines Corporation Inhibitori za ret za uporabu u liječenju raka koji ima ret alteraciju
JP7490635B2 (ja) * 2018-08-10 2024-05-27 ブループリント メディシンズ コーポレイション Ｅｇｆｒ変異がんの処置
KR20220016456A (ko) * 2019-04-16 2022-02-09 비바체 테라퓨틱스, 인크. 바이사이클릭 화합물
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN115279368B (zh) * 2019-11-20 2024-05-24 维瓦斯治疗公司 杂芳基化合物
US12448366B2 (en) 2020-05-29 2025-10-21 Rigel Pharmaceuticals, Inc. Solid forms of pralsetinib
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
KR102664454B1 (ko) * 2021-08-03 2024-05-09 한국생명공학연구원 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용
CN114681456A (zh) * 2022-02-23 2022-07-01 中山大学附属第六医院 Plx3397在结直肠癌的治疗中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076595A1 (en) * 2005-01-13 2006-07-20 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2016057370A1 (en) * 2014-10-06 2016-04-14 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
JP2009516707A (ja) 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 固形製剤
NZ572600A (en) * 2006-05-12 2011-08-26 Myrexis Inc 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
KR20150028857A (ko) 2006-10-27 2015-03-16 시그날 파마소티칼 엘엘씨 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
WO2009130342A1 (es) 2008-04-23 2009-10-29 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN105184228A (zh) * 2015-08-13 2015-12-23 小米科技有限责任公司 移动设备及其屏幕模组、指纹采集方法、装置及电子设备
JP6995058B2 (ja) * 2016-04-01 2022-02-21 シグナル ファーマシューティカルズ，エルエルシー （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076595A1 (en) * 2005-01-13 2006-07-20 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2016057370A1 (en) * 2014-10-06 2016-04-14 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
SG11201808388QA (en) 2018-10-30
NZ746554A (en) 2023-03-31
JP7014731B2 (ja) 2022-02-01
MX2018011992A (es) 2019-01-24
KR102356433B1 (ko) 2022-01-27
CN109069512B (zh) 2022-06-14
IL262007A (en) 2018-10-31
CA3018986A1 (en) 2017-10-05
IL262007B (en) 2022-12-01
CN109069512A (zh) 2018-12-21
MX379513B (es) 2025-03-11
CL2018002787A1 (es) 2019-01-18
AU2017241837A1 (en) 2018-10-25
EP3436018A1 (en) 2019-02-06
US20170281633A1 (en) 2017-10-05
SG10202009589UA (en) 2020-10-29
EA201892229A1 (ru) 2019-03-29
EA039392B1 (ru) 2022-01-21
WO2017173206A1 (en) 2017-10-05
IL262007B2 (en) 2023-04-01
KR20180126497A (ko) 2018-11-27
BR112018070163A2 (pt) 2019-01-29
US10576085B2 (en) 2020-03-03
JP2019510066A (ja) 2019-04-11
EP3436018A4 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
AU2017241837B2 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EP3131552B1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
US10513519B2 (en) Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
US9782427B2 (en) Methods for treating cancer using TOR kinase inhibitor combination therapy
EP3131550B1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy with a histone deacetylase inhibitor
HK40033324A (en) Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
HK1233943B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
HK1233943A1 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629859B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)